Hormonal therapy in metastatic prostate cancer: current perspectives and controversies
Ever since the introduction of androgen deprivation therapy (ADT) in prostate cancer, various controversial aspects of hormonal therapy have come to light. There has been tremendous progress in this area, marked by several important developments in the availability of various new androgen-suppressin...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2013-09-01
|
| Series: | Oncology Reviews |
| Subjects: | |
| Online Access: | http://www.oncologyreviews.org/index.php/or/article/view/226 |
| _version_ | 1797963122042994688 |
|---|---|
| author | Manish Garg Vishwajeet Singh Manoj Kumar Satya Narayan Sankhwar |
| author_facet | Manish Garg Vishwajeet Singh Manoj Kumar Satya Narayan Sankhwar |
| author_sort | Manish Garg |
| collection | DOAJ |
| description | Ever since the introduction of androgen deprivation therapy (ADT) in prostate cancer, various controversial aspects of hormonal therapy have come to light. There has been tremendous progress in this area, marked by several important developments in the availability of various new androgen-suppressing agents and refinements to the existing therapies. Parallel to these developments, various more debatable aspects have arisen in the use of these therapies with regards to their negative impact on quality of life parameters. Various modifications in these hormonal agents, their doses, and protocols have been tried in different scenarios in order to improve ADT tolerability. As a result, these controversies continue to evolve even with optimal use of the androgen ablation therapy. This review assesses the present status of hormonal therapy in metastatic prostate cancer and specifically deals with those aspects of androgen ablation therapy that are still a subject of debate. In spite of the fact that various trials have been conducted, some of which are still ongoing, the multitude of questions related to the best possible use of these hormonal agents have still not been answered. Treatment guidelines concerning these issues are continuing to evolve as progress continues to be made in this field. |
| first_indexed | 2024-04-11T01:23:23Z |
| format | Article |
| id | doaj.art-ffcd2db7b9034bb58be9afae3984a6f5 |
| institution | Directory Open Access Journal |
| issn | 1970-5557 1970-5565 |
| language | English |
| last_indexed | 2024-04-11T01:23:23Z |
| publishDate | 2013-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Oncology Reviews |
| spelling | doaj.art-ffcd2db7b9034bb58be9afae3984a6f52023-01-03T10:55:36ZengFrontiers Media S.A.Oncology Reviews1970-55571970-55652013-09-017110.4081/oncol.2013.e6184Hormonal therapy in metastatic prostate cancer: current perspectives and controversiesManish Garg0Vishwajeet Singh1Manoj Kumar2Satya Narayan Sankhwar3Department of Urology, King George Medical University, LucknowDepartment of Urology, King George Medical University, LucknowDepartment of Urology, King George Medical University, LucknowDepartment of Urology, King George Medical University, LucknowEver since the introduction of androgen deprivation therapy (ADT) in prostate cancer, various controversial aspects of hormonal therapy have come to light. There has been tremendous progress in this area, marked by several important developments in the availability of various new androgen-suppressing agents and refinements to the existing therapies. Parallel to these developments, various more debatable aspects have arisen in the use of these therapies with regards to their negative impact on quality of life parameters. Various modifications in these hormonal agents, their doses, and protocols have been tried in different scenarios in order to improve ADT tolerability. As a result, these controversies continue to evolve even with optimal use of the androgen ablation therapy. This review assesses the present status of hormonal therapy in metastatic prostate cancer and specifically deals with those aspects of androgen ablation therapy that are still a subject of debate. In spite of the fact that various trials have been conducted, some of which are still ongoing, the multitude of questions related to the best possible use of these hormonal agents have still not been answered. Treatment guidelines concerning these issues are continuing to evolve as progress continues to be made in this field.http://www.oncologyreviews.org/index.php/or/article/view/226prostate cancerandrogen ablation therapyintermittent hormonal therapycombined androgen blockageantiandrogens. |
| spellingShingle | Manish Garg Vishwajeet Singh Manoj Kumar Satya Narayan Sankhwar Hormonal therapy in metastatic prostate cancer: current perspectives and controversies Oncology Reviews prostate cancer androgen ablation therapy intermittent hormonal therapy combined androgen blockage antiandrogens. |
| title | Hormonal therapy in metastatic prostate cancer: current perspectives and controversies |
| title_full | Hormonal therapy in metastatic prostate cancer: current perspectives and controversies |
| title_fullStr | Hormonal therapy in metastatic prostate cancer: current perspectives and controversies |
| title_full_unstemmed | Hormonal therapy in metastatic prostate cancer: current perspectives and controversies |
| title_short | Hormonal therapy in metastatic prostate cancer: current perspectives and controversies |
| title_sort | hormonal therapy in metastatic prostate cancer current perspectives and controversies |
| topic | prostate cancer androgen ablation therapy intermittent hormonal therapy combined androgen blockage antiandrogens. |
| url | http://www.oncologyreviews.org/index.php/or/article/view/226 |
| work_keys_str_mv | AT manishgarg hormonaltherapyinmetastaticprostatecancercurrentperspectivesandcontroversies AT vishwajeetsingh hormonaltherapyinmetastaticprostatecancercurrentperspectivesandcontroversies AT manojkumar hormonaltherapyinmetastaticprostatecancercurrentperspectivesandcontroversies AT satyanarayansankhwar hormonaltherapyinmetastaticprostatecancercurrentperspectivesandcontroversies |